@kfhoz If new bone drugs are approved, it will be interesting to see if the drug companies pass any savings resulting from less expensive trials on to the customers.

I found this info on some of the current bone drug companies:
Amgen's profits from Evenity have shown significant growth, with sales increasing 39% year-over-year to $599 million in the fourth quarter of 2025 and a total annual increase of 34% for the full year. In the first quarter of 2026, Evenity sales rose by 27% to $562 million, maintaining a strong market presence.

In 2021, Radius Health reported net revenue of $219 million from sales of Tymlos, which was an increase from $208 million in 2020. The company aims for Tymlos net revenue of $232 million in 2022.

Eli Lilly, the company that sells Forteo, reported $69.90 million in net sales for Forteo in a recent quarter, which represents a year-over-year change of -52.8%. This decline indicates a significant drop in sales compared to previous periods.

Amgen, the company that sells Prolia, reported an overall revenue increase of 6% for the first quarter of 2026, totaling $8.6 billion. However, Prolia's sales specifically were down 34% to $727 million during the same period due to biosimilar competition.